Literature DB >> 33097935

Hepatitis A Person-to-Person Outbreaks: Epidemiology, Morbidity Burden, and Factors Associated With Hospitalization-Multiple States, 2016-2019.

Megan G Hofmeister1, Jian Xing1, Monique A Foster1, Ryan J Augustine1, Cole Burkholder2, Jim Collins2, Shannon McBee3, Erica D Thomasson3,4, Douglas Thoroughman4,5, Mark K Weng1, Philip R Spradling1.   

Abstract

BACKGROUND: Since 2016, the United States has experienced person-to-person hepatitis A outbreaks unprecedented in the vaccine era. The proportion of cases hospitalized in these outbreaks exceeds historical national surveillance data.
METHODS: We described the epidemiology, characterized the reported increased morbidity, and identified factors associated with hospitalization during the outbreaks by reviewing a 10% random sample of outbreak-associated hepatitis A cases in Kentucky, Michigan, and West Virginia-3 heavily affected states. We calculated descriptive statistics and conducted age-adjusted log-binomial regression analyses to identify factors associated with hospitalization.
RESULTS: Participants in the random sample (n = 817) were primarily male (62.5%) with mean age of 39.0 years; 51.8% were hospitalized. Among those with available information, 73.2% reported drug use, 14.0% were experiencing homelessness, 29.7% were currently or recently incarcerated, and 61.6% were epidemiologically linked to a known outbreak-associated case. Residence in Michigan (adjusted risk ratio [aRR] = 1.8), being a man who has sex with men (aRR = 1.5), noninjection drug use (aRR = 1.3), and homelessness (aRR = 1.3) were significantly (P < .05) associated with hepatitis A-related hospitalization.
CONCLUSIONS: Our findings support current Advisory Committee on Immunization Practices recommendations to vaccinate all persons who use drugs, men who have sex with men, and persons experiencing homelessness against hepatitis A. Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Entities:  

Keywords:  United States; disease outbreaks; hepatitis A; hospitalization; vaccine-preventable diseases

Year:  2021        PMID: 33097935     DOI: 10.1093/infdis/jiaa636

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

1.  The ZCCHC14/TENT4 complex is required for hepatitis A virus RNA synthesis.

Authors:  You Li; Ichiro Misumi; Tomoyuki Shiota; Lu Sun; Erik M Lenarcic; Hyejeong Kim; Takayoshi Shirasaki; Adriana Hertel-Wulff; Taylor Tibbs; Joseph E Mitchell; Kevin L McKnight; Craig E Cameron; Nathaniel J Moorman; David R McGivern; John M Cullen; Jason K Whitmire; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-07       Impact factor: 12.779

2.  Prevalence and Types of Drugs Used Among Hepatitis A Patients During Outbreaks Associated with Person-to-Person Transmission, Kentucky, Michigan, and West Virginia, 2016-2019.

Authors:  Megan G Hofmeister; Alice Asher; Christopher M Jones; Ryan J Augustine; Cole Burkholder; Jim Collins; Monique A Foster; Shannon McBee; Douglas Thoroughman; Erica D Thomasson; Mark K Weng; Phillip R Spradling
Journal:  J Appalach Health       Date:  2022-02-13

3.  Acute Hepatitis A Viral Infection in People With HIV With Previously Documented Hepatitis A Immunity or Appropriate Vaccination: A Case Series.

Authors:  Stephanie E McLaughlin; Jason D Simmons; Hilary Armstrong; Elysia Gonzales; Robert M Rakita; Jeffrey S Duchin; Rena C Patel
Journal:  Open Forum Infect Dis       Date:  2021-07-27       Impact factor: 3.835

4.  Antiviral adsorption activity of porous silicon nanoparticles against different pathogenic human viruses.

Authors:  Liubov A Osminkina; Svetlana N Agafilushkina; Ekaterina A Kropotkina; Nikolay Yu Saushkin; Ivan V Bozhev; Sergei S Abramchuk; Jeanne V Samsonova; Alexandra S Gambaryan
Journal:  Bioact Mater       Date:  2021-06-16

Review 5.  Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment.

Authors:  Marion Migueres; Sébastien Lhomme; Jacques Izopet
Journal:  Viruses       Date:  2021-09-22       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.